Figure 1. . Treatment preference between ravulizumab and prior eculizumab treatment by factor for (A) adult patients and (B) caregivers of pediatric patients.

For survey items relating to concerns (e.g. concern related to infusion), respondents indicated which treatment they preferred to overcome their concern. The binomial test was used to compare the proportion of those who indicated any preference for ravulizumab versus those who indicated either ‘no preference’ or any preference for eculizumab.

aHUS: Atypical hemolytic uremic syndrome.